impli market capit
catch momentum myelofibrosi initi
initi coverag srra outperform rate price target base
view signific commerci potenti compani main asset
momelotinib evalu registr clinic trial myelofibrosi
mf patient previous treat jak inhibitor believ current mf patient
primarili administ ruxolitinib often eventu discontinu treatment
due sever factor includ diseas progress myelosuppress new
option welcom address mf symptom view momelotinib well
posit secur treatment given uniqu pharmacolog properti prior
clinic trial publish literatur detail analysi insid
momelotinib inhibitor induc signific clinic
consist anemia benefit impli potenti applic drug
therapi ml also believ opportun momelotinib use
mf patient anemia irrespect time prior jak exposur
june srra announc plan momentum trial rais
capit financ studi issu prefer stock warrant subsequ
back compani well-known institut healthcar investor
experienc manag favor trial design momentum high unmet need
mf patient anemia larg commerci opportun lead us believ
srra significantli under-valued
estim momelotinib blockbust potenti rel high
probabl clinic commerci success comparison inci
inhibitor ruxolitinib launch current ww revenu
potenti reach peak anoth inhibitor fedratinib acquir
celgen januari deal fedratinib studi
encourag momentum trial princip investig dr srdan
verstovsek also princip investig mf pivot
trial ruxolitinib led fda approv thu establish lead
author jak inhibit hematolog disord opinion
price target base dcf valuat methodolog
assum wacc residu growth rate
view appropri given srra alreadi financ trial market
capit would around base potenti dilut share
year price histori srra
clinic
therapeut treatment
patient cancer engag
busi research develop
commerci therapi
treatment patient cancer
found may sierra
headquart vancouv canada
analyst certif import disclosur see disclosur
outperform rate srra base belief
share under-valued base evalu compani
main asset momelotinib registr clinic trial
myelofibrosi patient previous treat jak inhibitor
think current mf patient primarili administ
ruxolitinib first-lin eventu discontinu current treatment
due sever factor includ diseas progress
new second-lin option need address mf
symptom believ momelotinib well posit
secur treatment given uniqu chemic structur prior
clinic trial publish literatur
activ momelotinib demonstr registr momentum
revers split srra stock
period updat momentum trial
updat retrospect analysi simplifi studi
dec momelotinib tansfus data
revers split srra stock
updat momentum trial enrollment/progress
addit data analys eha
top-line data momelotinib
posit differenti momelotinib activ momentum
novel momelotinib trial cancer indic
financ greater
advanc pipelin asset
acquisit signific premium
expect
momelotinib activ momentum trial disappoint result
momentum clinic trial take longer expect and/or
show statist signific
competit landscap mf limit momelotinib commerci
price target srra base dcf valuat methodolog assum wacc residu
growth rate anticip launch momelotinib peak sale patent expir forecast ww
risk-adjust momelotinib sale driven momelotinib mf indic probabl success momelotinib
mf indic mf anemia indic
key downsid risk price target clinic develop regulatori risk momelotinib addit risk includ build
commerci infrastructur target indic higher anticip competit mf agent above-averag stock-pric
volatil owe stock microcap statu limit float upsid risk includ acquisit signific premium better
expect clinic data momelotinib
note see srra stock trade specul appropri risk toler investor
initi coverag sierra oncolog srra outperform rate
price target base view signific commerci potenti
compani main asset momelotinib evalu phase registr
clinic trial myelofibrosi mf patient previous treat jak
inhibitor price target repres potenti upsid current trade level
believ current mf patient primarili administ ruxolitinib first-lin
treatment often eventu discontinu treatment due sever factor includ diseas
progress advers event new second-lin treatment option like
welcom address mf symptom view momelotinib well posit secur
treatment given uniqu chemic pharmacolog properti prior clinic trial
result publish literatur
momelotinib dual inhibitor induc signific
clinic consist anemia benefit via inhibit make
potenti applic drug even broader simpli therapi mf believ
possibl momelotinib use mf patient anemia irrespect
time prior jak exposur could lead treatment advanc mf patient
june srra announc plan momentum trial rais capit
financ studi issu prefer stock warrant follow news srra
share experienc signific declin led trade level
howev back compani well-known healthcar institut investor
experienc manag team favor trial design momentum high unmet need
mf patient anemia larg commerci opportun momelotinib lead us
believ srra stock significantli under-valued estim momelotinib
blockbust potenti high probabl clinic commerci success
srra current trade level suggest market capit base basic share
count base dilut share count accord latest press releas
sec file srra common share potenti dilut share
base dcf analysi estim market cap srra divid
dilut share count give us price target
comparison incyt inhibitor ruxolitinib jakafi launch
current ww sale drug potenti peak revenu accord
estim anoth inhibitor fedratinib acquir celgen januari
deal fedratinib studi
momentum trial princip investig dr srdan verstovsek dr verstovsek
also princip investig mf pivot trial jakafi led
regulatori approv
believ momentum certain extent de-risk studi given momelotinib
alreadi data two previou mf studi run gilead assum
probabl success po momentum commerci success reach
estim sale
import given mf patient anemia and/or low platelet count limit
option improv symptom believ momelotinib could address need
patient clinic effect way
price target srra base dcf valuat
methodolog assum weight averag cost capit wacc
residu growth rate view appropri given srra
alreadi financ clinic trial cash runway momelotinib patient
expir expect earliest possibl late
end srra cash cash equival addit gross
financ proce announc novemb srra current market
capit around base basic share base potenti
includ srra early-stag candid valuat analysi re-
assess contribut valuat if/when pipelin advanc
assum probabl success base potenti target label momelotinib
po momelotinib mf patient previous treat jak inhibitor
believ momelotinib previou data two trial run may
support nda file compar arm momentum trial danazol
appear favor agent show differenti clinic efficaci given
po momelotinib mf patient anemia regardless prior
treatment believ possibl physician may use momelotinib
mf patient anemia given half ruxolitinib patient requir
dose reduct due myelosuppress momelotinib could becom
clinic prefer option patient
key downsid risk price target includ clinic develop risk
momelotinib registr trial mf patient addit risk come
build commerci infrastructur cancer indic post-regulatori approv
grant less expect sale due higher anticip
competit failur gain support physician commun us/eu payer
srra may requir signific addit fund pre-launch commerci oper
form dilut equiti sierra stock current micro-cap categori usual
associ above-averag stock volatil moreov srra limit float may add
key upsid risk price target includ acquisit signific premium
current share price better expect clinic data believ single-asset
oncolog compani may potenti acquisit target larg biopharma compani
upcom srra catalyst includ updat retrospect analysi
studi present american societi hematolog
confer decemb also think potenti updat
momentum studi could serv import catalyst stock
moreov addit retrospect analys studi
may provid valid momelotinib clinic profil may facilitate/reinforc
also expect srra reverse-split stock meet list requir
suspect split ratio may lead stock price turn open
door addit institut investor otherwis would invest stock trade
certain threshold per share
exhibit catalyst calendar srra
histori stock price
srra stock price ytd vs
nbi current institut ownership unknown given recent prefer stock
warrant deal septemb institut investor own
compani mangrov partner capit manag percept advisor
renaiss technolog prosight manag baker brother citadel among
top sharehold
factset oppenheim co note result view indic futur result
prefer stock warrant deal
four major healthcar fundsvivo capit longitud capit orbim advisor
abingworthhav particip gross financ momentum trial
transact provid capit srra financ momelotinib mf trial
top-lin result announc despit signific dilut
addit share think financ provid sophist institut investor
signal confid execut trial
exhibit srra prefer stock warrant financ announc june close novemb
srra also announc agre reduc momelotinib commerci royalti rate
elimin mileston payment exchang approxim equiti stake
srra warrant purchas addit stake believ
announc potenti dilut would provid incent manag
develop momelotinib would open door potenti srra acquisit
futur assum lower royalti rate acquisit like
believ decemb srra dilut share given
option warrant announc compani suffici cash financ
momentum trial top-lin result
srra vancouv canada-bas clinical-stag biopharmaceut compani focus
hematolog oncolog
august srra acquir drug candid momelotiniba potent
select oral bioavail dual janu kinas
activin receptor type inhibitor momelotinib investig two complet
trial treatment myelofibrosi
clinic benefit well achiev splenic volum reduct constitut symptom
srra paid up-front potenti aggreg mileston payment
larg associ commerci sale drug potenti tier
royalti accord estim novemb agreement
amend reduc royalti estim elimin
larg mileston payment exchang stock ownership srra warrant
obtain addit ownership
srra current run momentum trial momelotinib mf patient
myelofibrosi seriou life-threaten stem-cel deriv clonal myeloprolif
neoplasm present either de novo primari myelofibrosi follow previous
diagnos polycythemia vera essenti thrombocythemia
constitut symptom night sweat fever cachexia bone marrow reticulin
collagen fibrosi increas risk leukem transform well symptom
associ bone pain pruritu thrombosi relat bleed set
thrombocytopenia platelet dysfunct symptomat enlarg spleen
liver need red blood cell transfus cachexia mf
associ symptom result greatli compromis qualiti life onset usual age
older patient shorten surviv
first fda-approv medicin mf ruxolitinib jakafi becam avail
base result two random studi demonstr increas
proport patient show greater reduct spleen volum week
also show improv patient symptom score
second mf treatment fedratinib inreb approv fda
fedratinib oral kinas inhibitor activ wild type mutat
activ janu associ kinas fms-like tyrosin kinas
cell model express mutat activ fedratinib reduc
phosphoryl stat inhibit cell prolifer induc apoptot cell death
mf market domin ruxolitinib estim annual us sale
mf alon includ sale indic assum
elig mf patient us around patient
ruxolitinib ex-u sale report novarti estim ex-u sale
ruxolitinib mf indic total global mf sale
grow estim global sale ruxolitinib mf indic may reach peak
sale upcom year
exhibit jakafi market penetr sale
bmy/celg fedratinib acquir celgen approv
mf patient
fedratinib regulatori review base publish materi fda assum
ruxolitinib high discontinu rate year patient
low platelet count requir dose modif could advers impact ruxolitinib
due high unmet medic need mf patient fda approv fedratinib even
constel bet inhibitor current clinic studi combin ruxolitinib
mf patient success bet inhibitor improv spleen reduct mf
patient howev dont view bet inhibitor signific risk factor mf sale
forecast momelotinib given momelotinib intend mf patient mf
patient anemia
exhibit bet inhibit may potenti enhanc jak inhibit mf
acquir momelotinib part deal
momelotinib time candid studi mf patient
purpos deal grow gild hematology/oncolog portfolio
acquisit start random clinic trial simplify-
report result momelotinib show non-inferior ruxolitinib splenic
respons rate srr superior ruxolitinib transfus independ rate
transfus depend rate transfus requir endpoint
missedtot symptom score tss non-inferior srr superior
endpoint momelotinib trial miss think
trial ineffici somewhat confus design multipl superiority/non-inferior
endpoint reason decid pursu clinic develop
also think time momelotinib develop
compani focus hiv hcv cardiovascular inflamm portfolio
rather hematolog brought all-tim high sale
come antivir product
august gilead out-licens momelotinib back team initi develop
sierra oncolog ceo nick glover ceo cash
up-front deal potenti signific mileston royalti
srra team saw momelotinib opportun re-analyz and/or final
clinic trial submit new drug applic nda mf indic
srra conduct comprehens review data two trial momelotinib
well phase open-label translat biolog trial
momelotinib transfusion-depend subject mf analys across varieti
dataset appear show consist benefit three cardin diseas manifest
mf across spectrum intermediate-high risk patient jak-nav jak-
expos patient show anemia transfus depend constitut symptom
enlarg spleen consist compound differenti inhibit
srra launch registr momentum trial target top-
line readout
previou two trial run test
momelotinib myelofibrosi
multipl reason endpoint miss view one
main reason mf momelotinib test best avail therapi
bat mainli compris ruxolitinib
exhibit lack stratif tss
despit momelotinib miss sever pre-specifi endpoint still show consist
improv anemia-rel endpoint transfus dependence/independ
exhibit momelotinib show consist improv depend mf
anemia myelosupress remain major challeng mf patientsboth jak-nav
jak-expos opinion support numer public studi kol
momentum studi srra decid pursu low hang fruit secur
momelotinib run danazol drug approv fda mf
patient anemia danazol recommend though nation comprehens
cancer network nccn european societi medic oncolog esmo
guidelin base small studi show respons rate
patient transfus depend
momelotinib consist show transfus respons rate two
trial cross-compar data studi reason assum
momelotinib potenti beat danazol head-to-head trial
exhibit quot medic oncologist impli anemia major unmet need mf
model momelotinib mf
meta-analysi variou mf epidemiolog studi suggest preval mf
patient assum around mf patient us line
leader mf suggest mf patient us elig
ruxolitinib also disclos elig patient current receiv
ruxolitinib market penetr steadili grow trend
assum given year patient discontinu ruxolitinib due diseas
progress base follow-up studi publish
princip investig dr srdan verstovsek multipl reason discontinu
includ withdraw death diseas progress howev want
conserv start gradual increas number
refer fda assum discontinu rate ruxolitinib year
like due myelosupress
final assum market penetr momelotinib mf year
also assum monthli cost treatment current price
fedratinib gross-to-net adjust match current price
row revenu assum ratio momelotinib rest world us
revenu number deriv current ratio row us sale ruxolitinib
mf indic remind ruxolitinib current annual sale three
indicationsmf pv gvhdand sale driven mf indic
mf indic risk-adjust estim sale think trial
rel high chanc approv given compar arm danazol drug
even approv mf indic recommend nccn best
model momelotinib mf/anemia
model momelotinib sale mf patient anemia low platelet count
repeat initi step mf except count patient
current ruxolitinib patient
multipl reason mf patient current ruxolitinib
includ anemia low platelet count prior exposur ruxolitinib discontinu
due progress withdraw other
mayo clinic ran analysi mf patient period prior
approv first jak inhibitor ruxolitinib analysi jak-nav patient
show low hemoglobin level requir transfus
low platelet count per
momelotinib mf sale momelotinib mf sale sale sale price treatment launch mth gross-to-net discount price current mf patient popul yoy growth preval mf patient elig elig market share sale ruxolitinib mf patient progress ruxolitinib given elig market share momelotinib use price yoy growth discount sale momelotinib mf mf anemia adj net sale row mf patient row sale adj net sale sierra oncolog
exhibit mayo clinic analysi mf patient
tefferi et al one thousand patient primari myelofibrosi mayo clinic experi
analysi mf patient low count would need transfus went
median patient ruxolitinib may need momelotinib due
anti-anemia benefit
also assum gradual market penetr momelotinib sub-group
mf patient
final assum probabl indic sure whether
fda would will grant wide label momelotinib includ jak-
nave patient cant precis estim number jak-nav patient well
ii whether nccn would recommend physician administ
momelotinib anem low-platelet mf patient without first expos
ruxolitinib howev note mani exampl past nccn went
beyond fda label recommend panel think best patient
matter fda approv interesting/relev exampl danazolth drug
recommend nccn mf patient anemia fda approv danazol
endometriosi fibrocyst breast diseas hereditari angioedema
srra number early-stag asset cancer
indic compani indic look non-dilut financ advanc early-
stage candid howev valuat purpos includ drug
candid model appropri establish either potenti sale
probabl success indic drug candid time
momelotinib mf anemiatot sale momelotinib mf sale sale sale price treatment launch mth gross-to-net discount price current mf anemia patient popul yoy growth preval mf patient elig elig market share patient patient low platelet count anemia requir elig market share momelotinib mf anemia use price yoy growth discount sale momelotinib mf mf anemia adj net sale row mf anemia patient row sale adj net sale sierra oncolog
us srra appear patent cover underli core chemistri
well activ pharmaceut ingredi srra current least three us patent
base latest fling expir given provis
hatch-waxman act suspect momelotinib receiv exclus period us
last least potenti
europ srra appear similar exclus period suspect last
least potenti
one latest pct ww patent file titl momelotinib
treat diseas
exhibit one srra pct patent file
srdan verstovsek md phd depart leukemia md anderson cancer center
dr verstovsek medic oncologist professor depart leukemia
univers texa md anderson cancer center houston tx obtain
medic doctor degre univers zagreb zagreb croatia dr verstovsek
clinic translat research focus understand biolog
develop new therapi myeloprolif neoplasm mpn unit energi
resourc inc professor medicin director clinic research center
mpn md anderson princip investig clinic trial
test novel therapi patient mpn publish peer-
review manuscript dr verstovsek activ involv nation patient group
frequent invit speaker mpn nation intern
award celgen young investig award clinic research
hematolog award distinguish alumnu award divis
cancer medicin md anderson dr verstovsek award annual
irwin krakoff award excel clinic research divis cancer
medicin md anderson distinguish lectur award societi
hematolog oncolog dr verstovsek elect member
american societi clinic investig recognit contribut
physician-scientist award pearl walter faculti
achiev award clinic research md anderson cancer center
nick glover phd presid chief execut offic
dr glover accomplish life scienc profession extens strateg financi
oper experi biotechnolog sector evidenc demonstr valu
creation success outcom previous dr glover serv presid
chief execut offic ym bioscienc inc publicli trade oncolog drug
develop compani acquir februari ym lead drug
candid momelotinib oral administ jak inhibitor develop
treatment myelofibrosi hematolog disord prior dr glover
serv presid ceo viventia inc public trade
biopharmaceut compani focus develop monoclon antibodi
technolog dr glover also previous serv invest manag md
capit life scienc ventur capit firm current serv board director
pharma inc compani develop novel therapi hematolog oncolog
dr glover hold bsc hon chemistri univers east anglia
chemistri univers british columbia phd chemistri simon
dr klenck accomplish oncolog drug develop demonstr track record
success made substanti contribut develop approv
numer signific oncolog product previous dr klenck serv senior
vice presid develop subsidiari amgen inc
januari june prior group medic director product
develop oncolog genentech inc join compani juli
period led varieti oncolog program includ kyproli
carfilzomib kadcyla ado-trastuzumab emtansin avastin bevacizumab tarceva
erlotinib prior dr klenck serv medic director chiron corpor
biotechnolog compani later acquir ag assist
professor medicin univers california san francisco medic center dr
klenck hold bs indiana univers md univers california
dr kowalski extens experi phase phase iv drug develop
clinic trial execut wide varieti therapeut area includ oncolog dr
kowalski recent chief medic offic senior vice presid
arbutu biopharma biotechnolog compani devot discov develop
cure chronic hepat prior held posit tekmira
biopharmaceut compani focus develop therapeut base rna
interfer util lipid nanoparticl deliveri technolog oncolog infecti diseas
metabol clinic indic prior join tekmira dr kowalski work
oncolog inflamm therapeut area inc follow gilead
acquisit ym bioscienc inc dr kowalski
vice presid regulatori affair dr kowalski experi also encompass
vice presid medical/regulatori affair viventia
biotechnolog inc senior director medic affair aaipharma inc dr
kowalski hold rutger univers ph univers
kansa school medicin complet postgradu train intern
medicin infecti diseas duke univers harvard medic school
board certifi
mr jagpal join sierra oncolog februari chief offic cfo
previous mr jagpal cfo qlt inc dual-list biotechnolog compani
also base vancouv tenur assist qlt develop financ
capabl deal sever growth phase includ rais capit
complet sever acquisit prior join qlt held senior financ
posit pivot corpor inc kpmg llp mr jagpal
charter profession account charter busi valuat hold
 johnson graduat school manag cornel univers
queen univers kingston
board member invest firm
exhibit srra board member invest firm
gaurav aggarw md serv manag director capit llc
healthcar focus invest firm sinc octob focus
invest life scienc compani dr aggarw previous serv chief
busi offic manag director investor growth capit
gener partner panorama capit ventur capit fund earlier
career dr aggarw associ jpmorgan partner llc privat equiti
divis jpmorgan co dr aggarw previous serv board
director inc acquir horizon pharma plc microlin
inc sever privat held biopharmaceut compani dr aggarw
receiv md columbia univers colleg physician surgeon bs
agricultur econom cornel univers
mona ashiya phd current orbim advisor llc healthcar focus
invest firm orbim sinc involv
number invest public privat biotech compani dr ashiya receiv
ba univers california berkeley phd cellular molecular
development biolog univers pittsburgh
josh richardson md serv manag director longitud capit sinc
februari focus invest biotechnolog compani
septemb februari dr richardson serv public equiti analyst
healthcor manag manag small mid-cap biotechnolog
invest dr richardson receiv bs biomed scienc univers
south florida md univers virginia
andrew sinclair phd serv variou posit sinc novemb
abingworth llp life scienc invest group current serv
portfolio manag dr sinclair current serv board director soleno
therapeut inc verona pharma plc member institut charter
account england wale dr sinclair receiv bsc microbiolog
king colleg london phd chemistri genet engin bbsrc
institut plant scienc norwich
expect risk-adjust sale srra reach ww driven two
indic momelotinib second-lin mf mf anemia assum
probabl success momelotinib mf probabl success
momelotinib mf anemia assum launch momelotinib
assum monthli net price momelotinib par current estim
net price ruxolitinib fedratinib assumpt annual growth us estim
price line long-term project growth
exhibit forecast srra
sierra oncolog except per share data fy risk-adjust revenues- momelotinib mf mf mf anemia- mf anemia revenu un-adjusted- goodscogs- royalti gild- royalti profit- oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op ex sg total oper expens cog royalti oper incom interest interest expense- total non-oper incom pre-tax incom incom tax benefit tax incom basic share outstand share outstand ep ep oppenheim co estim compani data srra outperform
price target srra base dcf valuat
methodolog assum wacc residu growth rate
anticip launch momelotinib peak sale patent expir
srra septemb cash balanc
forecast ww risk-adjust sale momelotinib driven momelotinib
mf indic probabl success momelotinib mf indic
mf anemia indic
exhibit dcf valuat srra except share
sierra oncolog fy asset cash current asset prepaid total current properti equip oper leas right-of-us assets- total liabilitiescurr liabil account accru term loan current portion- total current term loan- oper leas liabilities- total prefer stock- common addit paid-in accumul total stockhold total liabil sourc oppenheim co compani report
sierra oncolog fy incom adjustmentsstock-bas depreci non-cash chang oper asset liabilitiesprepaid expens accru account flow purchas properti chang restrict flow proce issuanc common prefer proce exercis common stock proce issuanc term loan net issuanc restrict cash plug- flow effect net increas decreas equival equival sourc oppenheim co compani report sierra oncolog
sierra oncolog srra discount analysi except per-shar data mn except per-shar data revenu royalti gross chang work work capit valu per sharediscount valu growth rateshar valu growth valu oppenheim srra outperform
momelotinib mf
probabl success
momelotinib mf risk-adjust
momelotinib mf anemia
probabl success
momelotinib mf anemia risk-adjust
good
royalti
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex sg
stock price compani mention report decemb
